9月15日，Tempus AI盘中上涨5.41%，报62.15美元/股，成交额1.64亿美元。
消息面上，公司近日接连释放多项利好。Tempus AI宣布正在构建包含10万条全基因组序列及纵向临床数据的多模态研究平台，长期目标扩展至100万基因组，初始数据集已通过早期采用者计划开放，预计明年年中全面上线。此外，公司获得美国高级卫生研究计划局（ARPA-H）最高950万美元资助，用于开发心衰护理领域的自主临床AI系统。近期多家投行亦密集发起覆盖，Cantor Fitzgerald给予"增持"评级及80美元目标价，Piper Sandler将评级上调至"增持"并将目标价大幅提升至76美元，市场情绪偏正面。
Tempus AI通过AI在医疗保健领域的实际应用，致力于释放精准医疗的潜力，将实验室结果与患者临床数据连接，实现个性化诊断。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.